Accordingly, Pharco created the first API factory in Egypt (Active Pharmaceutical Ingredients) specialized in manufacturing of modern Hep C therapies which are relatively affordable and efficient, all per cGMP requirements.
One million months’ worth of treatment was produced by Pharco pharmaceuticals, curing 500,000 patients in Egypt. The Halel wetamen was initiated, as a national screening plan aiming at covering the whole population. Up to this day 20,000 people were screened.
Pharco partnered with Prime Pharma to initiate Tour n Cure, an international program for medical tourism. The program encourages patients worldwide to visit Egypt for a week to do all needed medical check-ups, have the treatment course as prescribed by the best doctors, and enjoy the beauty of Egypt, at less than 80% of the worldwide cost. Lionel Messi, Dani Alves, and Ahmed Hossam (Mido) are currently active program ambassadors.
Gamal Esmat, M.D., Professor of Haepatology and Endemic Medicine at Cairo University and WHO viral hepatitis expert, presented advanced results of the abstract entitled: High Virologic Response Rate in Egyptian HCV-Genotype 4 Patients Treated with Ravidasvir (PPI-668) and Sofosbuvir: Results of a Large Multicenter Phase 3 Registrational Trial.
Dr. Gamal Esmat, representing Pharco, was the first Arab to present at the closing ceremony, where the major treatment protocols for the upcoming year are agreed upon.
The launching of Gratisovir took place in April, as an affordable and efficient oral Hepatitis C virus treatment.
*Gratisovir (active ingredient is Sofosbuvir)
An extension of the sterile, non-Ceph. At Pharco B International was established to produce small and large volume parenteral. A new, separate dedicated Hormone facility in Techno Pharma Egypt was established.
A separate Extension in Pharco B International for the production of water for injection in plastic ampoule
Launch of Pharco B International, starting with a dedicated facility for the production of Cephalosporin antibiotics for local and international markets.
To offer a wide range of pharmaceutical products to the Saudi Arabian market, Batterjee Pharmaceuticals KSA was established - after Pharco Pharmaceuticals joined with local competitor EIPICO and Batterjee Group in Kingdom of Saudi Arabia.
Acquisition of Amriya Pharmaceuticals, EEPI (European Egyptian Pharmaceutical Industry) and Techno Pharma Egypt (a local soft gelatin capsules manufacturer).
In compliance with cGMP regulations at the time, a new separate Beta-Lactam facility was constructed to avoid cross contamination with other products.
Majority partner shares in Pharco Pharmaceuticals were acquired by Dr. Hassan Abbas Helmy.
Establishment of R.P Scherer Egypt, in partnership with RP Scherer Corporation.
Establishment of Pharco Impex 93, which is the import, marketing, and distribution branch of Pharco in Romania.
January 14th to be exact was the operative date of Pharco Pharmaceuticals, as a local manufacturer of soft gelatin capsules, and introducing other dosage forms and antibiotics for the first time in Egypt.
Scientific office Vitanco was launched, importing soft gelatin capsule drugs from RP Scherer Germany.
In Alexandria, Glym pharmacy was established and started manufacturing in-house Aminophylline suppositories. *Aminophylline suppositories (highly effective and safe bronchodilators).